Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference

Feb 28, 2024

PHILADELPHIA, Feb. 28, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6th at 2:50 pm ET.

An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.

About Carisma 

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit

Shveta Dighe
Head of Investor Relations

Media Contact:
Julia Stern
(763) 350-5223

Cision View original content to download multimedia:

SOURCE Carisma Therapeutics Inc.